No Data
No Data
No Data
No Data
No Data
UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating
ACADIA Pharmaceuticals (ACAD) has an average rating of outperform and price targets ranging from $13 to $39, according to analysts polled by Capital IQ. Price: 16.97, Change: -0.14, Percent Change: -0
MT NewswiresMay 1 00:17
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shareholders Have Endured a 37% Loss From Investing in the Stock Five Years Ago
Yahoo FinanceApr 28 21:38
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Yahoo FinanceApr 25 04:05
ACADIA Pharmaceuticals (NASDAQ:ACAD) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
Simply Wall StApr 24 22:42
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health
BusinesswireApr 22 21:04
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
BusinesswireApr 20 04:05
No Data
No Data